Sign up | Log in



PR Today

Home >> Press Release

UCB and Biogen Idec Enter Agreements to Commercialize

Multiple Sclerosis and Hemophilia Therapies in Asia

 Relationship Leverages UCB’s Expertise and Presence in Asia to Bring Biogen Idec’s Innovative Therapies to Patients in New Markets
Bangkok, Thailand - 10 February 2014: UCB and Biogen Idec today announced that they have signed an exclusive agreement granting UCB the right to commercialize Biogen Idec products in South Korea, Hong Kong, China, Singapore, Malaysia and Taiwan, and both develop and commercialize products in Thailand.

As part of the relationship, Biogen Idec will supply UCB with its portfolio of multiple sclerosis therapies and investigational candidates, including TECFIDERA?, AVONEX?, TYSABRI? and FAMPYRA?. The relationship also includes ELOCTATE? and ALPROLIX?, Biogen Idec’s investigational long-acting recombinant-based treatments for hemophilia A and B, respectively.

“Our goal is to bring our innovative therapies to patients around the world as quickly and efficiently as possible,” said Carlos Dourado, Senior Vice President, Emerging Markets at Biogen Idec. “By leveraging UCB’s extensive resources, expertise and infrastructure in Asia, we are able to grow our footprint in critical Asian markets, get our therapies to patients as quickly as possible and create a foundation for further commercial success in this region.”

Mohamed Chaoui, Head of Asia Pacific at UCB, said: “As a patient centric biopharmaceutical company, UCB is delighted to work with Biogen Idec on delivering some of the most important breakthrough products in the treatment of multiple sclerosis and hemophilia to patients in Asia. This partnership is a strong complement in our goal to offer innovative specialty care therapeutic options to patients suffering from severe diseases.   It further supports our strategic goal to strengthen our leadership and expertise in biologics in both neurology and immunology in Thailand and the Asian region.

Mr. Chaoui added, “We are committed to broadening and deepening our presence in Asia and offering patients and healthcare providers around the Asian region access to new and innovative treatment options. This agreement is also an important step for our specialty focused expansion in Thailand. It will help drive our business growth in other Southeast Asian markets, which is one of UCB’s top strategic priorities.”

In Thailand, UCB intends to bring these medicines to the market from 2014 onwards, pending regulatory approval. The offerings are complementary to UCB’s existing CNS portfolio and will enable the company to rapidly increase its critical mass in Thailand, reinforcing its strategic presence in both public and private hospitals and specialist clinics that have the potential to leverage UCB’s broader range of innovative solutions. Further, the launch-ready offerings will accelerate UCB’s expansion into Thailand, which the company has identified as a strategic growth priority.

Reach Southeast Asia!
10- Nations, 560- Million Consumers
And $1 -Trillion Market
We are the Voice of Southeast Asia Media Kit
The only Media Dedicated to Southeast Asia Advertising Rates for Magazine
Online Ad Rates

Comment on this Article. Send them to

Letters that do not contain full contact information cannot be published.
Letters become the property of AseanAffairs and may be republished in any format.
They typically run 150 words or less and may be edited
submit your comment in the box below

Today's  Stories    February 11, 2014 Subsribe Now !
• Govt-farmer rice talks fail; farmers storm out of meeting Subcribe: Asean Affairs Global Magazine
• Annual forecast optimistic for locally produced export goods
Research Reports
on Thailand 2007-2008

• Textiles and Garments Industry
• Coffee industry
• Leather and footwear industry
• Shrimp industry

• Loans at MFIs grow to surpass $1 billionds
• President Sang attempts to entice increased Japanese investment
Asean Analysis                    7 February  2014 Advertise Your Brand
• Asean Analysis-February 7, 2014
Thai Democracy Faces Continuing Hurdles in the Wake of Elections
• Asean Analysis-February 7, 2014
China becomes largest investor in Laos
Asean Stock Watch    10 February 2014
• Asean Stock Watch-February 10, 2014
• Asean Analysis-February 7, 2014
Myanmar’s Constitutional Review Committee Shies Away from Needed Changes

The Biweekly Update
• The Biweekly Update  February 7, 2014

ASEAN NEWS UPDATES      Updated: 04 January 2011

 • Women Shariah scholars see gender gap closing
• Bank Indonesia may hold key rate as inflation hits 7 percent
• Bursa Malaysia to revamp business rules
• Private property prices hit new high in Singapore • Bangkok moves on mass transport
• Thai retailers are upbeat
• Rice exports likely to decline • Vietnamese PM projects 10-year socioeconomic plan


This year in Thailand-what next?

AseanAffairs   04 January 2011
By David Swartzentruber      

It is commonplace in journalism to write two types of articles at the transition point between the year that has passed and the New Year. As this writer qualifies as an “old hand” in observing Thailand with a track record dating back 14 years, it is time take a shot at what may unfold in Thailand in 2011.

The first issue that can’t be answered is the health of Thailand’s beloved King Bhumibol, who is now 83 years old. He is the world's longest reigning monarch, but elaborate birthday celebrations in December failed to mask concern over his health. More






1.  Verifier

1. Verifier

For security purposes, we ask that you enter the security code that is shown in the graphic. Please enter the code exactly as it is shown in the graphic.
Your Code
Enter Code

Home | About Us | Contact Us | Special Feature | Features | News | Magazine | Events | TV | Press Release | Advertise With us

Our Products | Work with us | Terms of Use | Site Map | Privacy Policy | Refund Policy | Shipping/Delivery Policy | DISCLAIMER |

Version 5.0
Copyright © 2007-2015 TIME INTERNATIONAL MANAGEMENT ENTERPRISES CO., LTD. All rights reserved.
Bangkok, Thailand